Avid Bioservices Inc (CDMO)

[eb0783]

Good find BioBS! This should answer entdoc's request for info. I particularly liked this part:

In this trial, there was a
lower incidence of vascular events in the docetaxel with bavituximab
3 mg/kg arm (n ¼ 1; DVT) than in the combined docetaxel
with placebo/bavituximab 1 mg/kg arm (n ¼ 5; DVT, PE, CVA).
There were no instances of clinically significant, treatmentemergent
bleeding, proteinuria, hypertension, or visceral perforation.
Further, vascular events in both arms of this trial did not
exceed those expected with docetaxel monotherapy or in the
general context of progressive advanced malignancy.30-33 Separately,
immune checkpoint inhibitors targeting CTLA4, PD1, and
PDL1 have been associated with numerous immune-related AEs,
including pneumonitis, colitis, hepatitis, hypophysitis, dermatitis,
and nephritis.1,34-37 In contrast, overt immune-related toxicities
have not been observed with bavituximab.

So in contrast to CTLA4, PD1, PDL1, "overt immune-related toxicities
have not been observed with bavituximab." Sounds kinda like a repeat of what Dr Thorpe was saying back in 2005.